IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx
This study has been completed.
Sponsor:
Donald T. Weed
Information provided by (Responsible Party):
Donald T. Weed, University of Miami
ClinicalTrials.gov Identifier:
NCT00843635
First received: February 12, 2009
Last updated: September 25, 2015
Last verified: September 2015
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Biological therapies, such as tadalafil, may stimulate the immune system in different ways and stop tumor cells from growing.
PURPOSE: This randomized clinical trial is studying how well tadalafil works in treating patients who are undergoing surgery for cancer of the oral cavity or oropharynx.
| Condition | Intervention |
|---|---|
| Head and Neck Cancer | Drug: Tadalafil Other: Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment |
| Official Title: | Pilot Study of Phosphodiesterase-5 Inhibitor Tadalafil (Cialis) as an Immunomodulator in Patients With Oral Cavity and Oropharyngeal Squamous Cell Carcinoma. |
Resource links provided by NLM:
Further study details as provided by Donald T. Weed, University of Miami:
Primary Outcome Measures:
- Ratio of MDSC Concentration in the Blood [ Time Frame: Baseline, End of Treatment at time of Surgery ]Ratio of the number of Myeloid Derived Suppressor Cells (MDSC) in the Blood, per treatment group, from Baseline to End of Treatment at Time of Surgery.
- Ratio of T-reg Cell Concentration in the Blood [ Time Frame: Baseline, End of Treatment at Time of Surgery ]Ratio of the number of regulatory T cells in the blood, per treatment group, from Baseline to End of Treatment at Time of Surgery..
- Ratio of Tumor-specific T-cell Concentration in the Blood [ Time Frame: Baseline, End of Treatment at Time of Surgery ]Ratio of the number of tumor specific T cells in the blood, per treatment group, from Baseline to End of Treatment at Time of Surgery.
Secondary Outcome Measures:
- Optimal Dosing Schedule for Tadalafil [ Time Frame: Baseline, End of Treatment at Time of Surgery. ]
- Number of Participants Experiencing Adverse Events [ Time Frame: From Day 1 to Day 20 ]Assessment of Treatment-related Side Effects. Number of participants experiencing adverse events
| Enrollment: | 35 |
| Study Start Date: | September 2008 |
| Study Completion Date: | April 2015 |
| Primary Completion Date: | April 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Arm A - Tadalafil 10mg
Patients will receive 10mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
|
Drug: Tadalafil
Given orally
Other Name: Cialis
|
|
Experimental: Arm B - Tadalafil 20mg
Patients will receive 20mg/day Tadalafil orally on days 1 - 20 in the absence of unacceptable toxicity.
|
Drug: Tadalafil
Given orally
Other Name: Cialis
|
|
Placebo Comparator: Arm C - Placebo
Patients receive oral placebo once daily on days 1-20 in the absence of unacceptable toxicity.
|
Other: Placebo
Given orally
|
Detailed Description:
OBJECTIVES:
- To analyze the phenotype and the function of the tumor-induced suppressive network associated with squamous cell carcinoma (SCC) of the head and neck in patients with SCC of the oral cavity or oropharynx treated with tadalafil followed by definitive surgical resection.
- To analyze the immune response before and after treatment with tadalafil to determine whether or not tadalafil treatment modulates in these patients.
- To compare two doses of tadalafil to determine whether there are measurable differences in immune response in these patients.
- To analyze treatment-related side effects of tadalafil at each of the two doses tested in these patients.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
- Arm I: Patients receive oral tadalafil once daily on days 1-20 in the absence of unacceptable toxicity.
- Arm II: Patients receive oral tadalafil (at a higher dose than in arm I) once daily on days 1-20 in the absence of unacceptable toxicity.
- Arm III: Patients receive oral placebo once daily on days 1-20 in the absence of unacceptable toxicity.
All patients undergo scheduled definitive surgical resection on day 23.
Patients undergo blood sample collection at baseline, on day 20, and at 6 weeks after surgical resection for correlative laboratory studies. Patients also undergo tumor tissue sample collection at baseline and at the time of surgical resection. Samples are analyzed for immunological markers by Fluorescence-activated cell sorting (FACS) and Immunohistochemistry (IHC).
After completion of study treatment, patients are followed periodically for at least 3 years.
Eligibility| Ages Eligible for Study: | 18 Years to 120 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
INCLUSION CRITERIA:
- Patients with surgically resectable oral cavity SCC, all subsites, T1 - T4, N0 - N3
- Patients with surgically resectable oropharyngeal SCC, all subsites, T1 - T2, N0 - N1
- Patients with surgically resectable T4 oropharyngeal SCC, all subsites, N0 - N3
- Patients must be 18 years old or older
EXCLUSION CRITERIA:
- Patients with previous surgical resection, radiation, or chemotherapy will be excluded to rule out possible effects of local tissue changes secondary to previous treatment
- Patients with surgically unresectable disease at primary site or regional lymph nodes
- Patients with T1 - T2 SCC oropharynx, N2 - N3
- Patients with T3 SCC oropharynx , N0 - N3
- Any patient for whom non-surgical therapy is recommended as treatment of choice after multidisciplinary treatment evaluation
- Patients with an altered mental status or not capacitated for their medical decision making
-
Patients with severe or unstable cardiac or cerebrovascular disease are excluded
- myocardial infarction within the last 90 days
- unstable angina or angina occurring during sexual intercourse
- New York Heart Association Class 2 or greater heart failure in the last 6 months
- uncontrolled arrhythmias
- hypotension (<90/50 mm Hg), or uncontrolled hypertension (>170/100 mm Hg)
- stroke within the last 6 months
- Left ventricle outflow obstruction.
- Pregnant and nursing mothers will not be enrolled given unknown effects to offspring
- Concurrent nitrate, alpha-blocker, or cytochrome P-450 inhibitor use
- Renal Insufficiency defined as creatinine clearance less than 51.
- Creatinine clearance will be determined by the following Cockcroft-Gault Equation: (140-age) * (Wt in kg) * (0.85 if female) / (72 * Cr)
- Patients with hepatic insufficiency.
- Patients currently taking a Phosphodiesterase (PDE) inhibitors for erectile dysfunction
- Patients who are immunocompromised, for reasons not directly related to patients malignancy
- Patients with significant alcohol or drug abuse
- Patients with unilateral blindness, hereditary retinal disorders, or increased risk of blindness
- Patients with unilateral deafness, history of hearing loss, hearing aid dependence, or clinically evident hearing loss
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00843635
Please refer to this study by its ClinicalTrials.gov identifier: NCT00843635
Locations
| United States, Florida | |
| University of Miami Sylvester Comprehensive Cancer Center - Miami | |
| Miami, Florida, United States, 33136 | |
Sponsors and Collaborators
Donald T. Weed
Investigators
| Principal Investigator: | Donald T. Weed, MD | University of Miami Sylvester Comprehensive Cancer Center |
More Information
Publications:
| Responsible Party: | Donald T. Weed, Professor, University of Miami |
| ClinicalTrials.gov Identifier: | NCT00843635 History of Changes |
| Other Study ID Numbers: |
20070918 SCCC-2008006 ( Other Identifier: UM/Sylvester Comprehensive Cancer Center ) |
| Study First Received: | February 12, 2009 |
| Results First Received: | June 3, 2015 |
| Last Updated: | September 25, 2015 |
Keywords provided by Donald T. Weed, University of Miami:
|
stage I squamous cell carcinoma of the lip and oral cavity stage I squamous cell carcinoma of the oropharynx stage II squamous cell carcinoma of the lip and oral cavity stage II squamous cell carcinoma of the oropharynx stage III squamous cell carcinoma of the oropharynx stage III squamous cell carcinoma of the lip and oral cavity |
stage IV squamous cell carcinoma of the oropharynx stage IV squamous cell carcinoma of the lip and oral cavity stage I verrucous carcinoma of the oral cavity stage II verrucous carcinoma of the oral cavity stage III verrucous carcinoma of the oral cavity stage IV verrucous carcinoma of the oral cavity |
Additional relevant MeSH terms:
|
Carcinoma, Squamous Cell Head and Neck Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Neoplasms by Site |
Tadalafil Phosphodiesterase 5 Inhibitors Vasodilator Agents Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Urological Agents |
ClinicalTrials.gov processed this record on September 21, 2017